References:
Ademuyiwa FO et al. The effects of Oncotype DX Recurrence Scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 2011;126(3):797-802. Abstract
Albain KS et al. Prognostic and predictive value of the 21-gene Recurrence Score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11(1):55-65. Abstract
Albain KS et al. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009;18(Suppl 3):141-5. Abstract
Albanell J et al. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol 2012;23(3):625-31. Abstract
Asad J et al. Does Oncotype DX Recurrence Score affect the management of patients with early-stage breast cancer? Am J Surg 2008;196(4):527-9. Abstract
Brewer NT et al. Improving communication of breast cancer recurrence risk. Breast Cancer Res Treat 2011;[Epub ahead of print]. Abstract
Chen E et al. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer. Am J Manag Care 2010;16(12):e333-42. Abstract
Cuzick J et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health Recurrence Score in early breast cancer. J Clin Oncol 2011;29(32):4273-8. Abstract
Dowsett M et al. Prediction of risk of distant recurrence using the 21-gene Recurrence Score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A transATAC study. J Clin Oncol 2010;28(11):1829-34. Abstract
Geffen DB et al. The impact of the 21-gene Recurrence Score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. Ann Oncol 2011;22(11):2381-6. Abstract
Gianni L et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005;23(29):7265-77. Abstract
Goldstein LJ et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26(25):4063-71. Abstract
Henry LR et al. The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 2009;99(6):319-23. Abstract
Ishibe N et al. Use of Oncotype DX in women with node-positive breast cancer. PLoS Curr 2011;3:RRN1249. Abstract
Joh JE et al. The effect of Oncotype DX Recurrence Score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist 2011;16(11):1520-6. Abstract
Kao KJ et al. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: Implications for treatment optimization. BMC Cancer 2011;11:143. Abstract
Kelly CM et al. Agreement in risk prediction between the 21-gene Recurrence Score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic classifier in early-stage estrogen receptor-positive breast cancer. Oncologist 2012;[Epub ahead of print]. Abstract
Kelly CM et al. Review of the clinical studies using the 21-gene assay. Oncologist 2010;15(5):447-56. Abstract
Kelly CM et al. Utility of Oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010;116(22):5161-7. Abstract
Knauer M et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010;103(12):1788-93. Abstract
Knauer M et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010;120(3):655-61. Abstract
Krijgsman O et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat 2011;[Epub ahead of print]. Abstract
Lee JJ, Shen J. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers? Am Surg 2011;77(10):1364-7. Abstract
Lo SS et al. Prospective multicenter study of the impact of the 21-gene Recurrence Score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28(10):1671-6. Abstract
Mamounas EP et al. Association between the 21-gene Recurrence Score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: Results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010;28(10):1677-83. Abstract
Mamounas EP et al. Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q&A and case study sampling. Clin Adv Hematol Oncol 2008;6(2 Suppl 3):1-8. Abstract
Mook S et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010;21(4):717-22. Abstract
Oratz R et al. Physician survey of the effect of the 21-gene Recurrence Score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer. J Oncol Pract 2011;7(2):94-9. Abstract
Paik S. Is gene array testing to be considered routine now? Breast 2011;20(Suppl 3):87-91. Abstract
Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007;12(6):631-5. Abstract
Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract
Partin JF, Mamounas EP. Impact of the 21-gene Recurrence Score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer. Ann Surg Oncol 2011;18(12):3399-406. Abstract
Richman AR et al. Knowledge of genomic testing among early-stage breast cancer patients. Psychooncology 2011;20(1):28-35. Abstract
Rutgers E et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase. Eur J Cancer 2011;47(18):2742-9. Abstract
Slodkowska EA, Ross JS. MammaPrint 70-gene signature: Another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn 2009;9(5):417-22. Abstract
Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26(5):721-8. Abstract
Straver ME et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010;119(3):551-8. Abstract
Subramanian J, Simon R. What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol 2010;7(6):327-34. Abstract
Tang G et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. Breast Cancer Res Treat 2011;127(1):133-42. Abstract
Tang G et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence Score alone and integrated with pathologic and clinical factors. J Clin Oncol 2011;29(33):4365-72. Abstract
Tian S et al. Biological functions of the genes in the MammaPrint breast cancer profile reflect the hallmarks of cancer. Biomark Insights 2010;5:129-38. Abstract
Wittner BS et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008;14(10):2988-93. Abstract